SA SANA Sana Biotechnology, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Sana's engineered insulin-producing islets have survived one year in humans without immunosuppression while still producing insulin, validating its immune-evasive anti-rejection technology. The author argues this solves the immunosuppression problem that led to a patient death in Vertex's VX880 trial, positioning Sana to be first to market by several years. A phase 1 trial of lab-grown insulin-producing cells is expected to start this year. The author notes insulin expression was reduced at 52 weeks, attributed to donor islet age rather than rejection.

Sana Biotechnology announced that its engineered insulin-producing islets survived in a human for 1 year without immunosuppression, validating its immune-evasive anti-rejection technology. The author argues this positions Sana to be first to market by several years for a type 1 diabetes cure, with a phase 1 trial of lab-grown insulin-producing cells starting this year. The author notes insulin expression was reduced at 52 weeks, attributed to donor islet age, but no rejection was observed.

The author argues Sana's engineered insulin-producing islets have survived one year in a human without immunosuppression while still producing insulin, validating its immune-evasion technology. The mechanism is that Sana's approach avoids the immunosuppression that caused a death in Vertex's competing VX880 trial, potentially making it first to market by several years. Sana will start a phase 1 trial of lab-grown insulin-producing cells this year, with the author expecting adequate insulin production for several years. The author notes insulin expression was reduced at 52 weeks, attributed to donor islet age.

The author argues Sana Biotechnology's immune-evasive insulin-producing islets have survived one year in a human without immunosuppression, validating its anti-rejection technology and positioning it as a potential first-to-market type 1 diabetes cure years ahead of competitors. The mechanism is that Sana's immune evasion avoids the need for immunosuppression, which the author notes caused a patient death in Vertex's VX880 trial. The catalyst is a Phase 1 trial of lab-grown insulin-producing cells starting this year, with the author expecting the cells to produce adequate insulin for several years. The author acknowledges insulin expression was reduced at 52 weeks, which the CEO attributed to donor islet age rather than rejection.